Hit enter to search or ESC to close
ERA4TBERA4TBERA4TB
  • The Project
  • Consortium
  • News
    • Events
    • Press
    • Newsletter
    • Video Library
  • Results
  • TB Facts
  • SharePoint
Category

News

News

ERA4TB welcomes CIM – Sant Pau (IIB Sant Pau) as New Partner

ERA4TB announced on the 4th Consortium Meeting that CIM – Sant Pau (IIB Sant Pau)…
IT Synapse
IT SynapseFebruary 1, 2022
News

The ERA4TB Scientific Advisory Board has been set up

Dr Gilla Kaplan, Ph.D. Former Director of the Global Health Program, Tuberculosis, at the Bill…
IT Synapse
IT SynapseFebruary 1, 2022
News

ERA4TB SCHEDULES THE 4TH CONSORTIUM MEETING ON 27TH AND 28TH OF JANUARY 2022

The ERA4TB 4th Consortium Meeting is taking place next 27th -28th January 2022 as a…
Inari Soininen
Inari SoininenDecember 3, 2021
News

TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study

TB Alliance announced that on December 1, 2020, the first dose was administered to a…
IT Synapse
IT SynapseDecember 17, 2020
News

ERA4TB at the Union World Conference

From 22 to 24 October took place the 51st Union World conference on lung health.…
Inari Soininen
Inari SoininenNovember 30, 2020
News

The potential impact of the Covid-19 response on tuberculosis in high-burden countries: a modelling analysis

Developed by Stop TB Partnership in collaboration with Imperial College, Avenir Health, Johns Hopkins University…
admin
adminMay 20, 2020

Recent Posts

  • ERA4TB 5th Consortium Meeting: First F2F meeting in Madrid after the pandemic
  • 5th Consortium Meeting on 20th and 21st of June 2022 – After 2 years, ERA4TB meets again face to face in Madrid
  • ERA4TB welcomes CIM – Sant Pau (IIB Sant Pau) as New Partner
  • The ERA4TB Scientific Advisory Board has been set up
  • ERA4TB 4th Consortium Meeting: The Time to Make a Difference

Categories

  • Event
  • News
  • Press

TWITTER

ERA4TB ProjectFollow

European Regimen Accelerator for Tuberculosis. Grant Agreement number: 853989 — ERA4TB

ERA4TB Project
Retweet on TwitterERA4TB Project Retweeted
27 Jun

The @AMRAccelerator project @UNITE4TB now also featured on https://amr-accelerator.eu/ 👉 Check it out to learn all about their fight against #AMR and #TB.

#OneHealth #HealthForAll #AntimicrobialResistance

Reply on Twitter 1541383449445105664Retweet on Twitter 15413834494451056646Like on Twitter 15413834494451056645Twitter 1541383449445105664
Retweet on TwitterERA4TB Project Retweeted
24 Jun

Wonderful ERA4TB meeting finally in presence! Thanks to my great group and in particular to Laurent and Giulia! - 5th EC ERA4TB meeting, Madrid (Spain) @DBB_UniPV @unipv @IMI_ERA4TB

Reply on Twitter 1540219309200474112Retweet on Twitter 15402193092004741124Like on Twitter 15402193092004741128Twitter 1540219309200474112
Retweet on TwitterERA4TB Project Retweeted
23 Jun

Curious to find out more about the @IMI_ERA4TB project? Download their info brochure and read all about their dedication to combat #TB 👉https://bit.ly/3bma1WO ERA4TB is part of the @AMRAccelerator projects family.

#AMR #tuberculosis #OneHealth #HealthForAll

Reply on Twitter 1539927200467656706Retweet on Twitter 15399272004676567065Like on Twitter 15399272004676567067Twitter 1539927200467656706
Retweet on TwitterERA4TB Project Retweeted
21 Jun

Join our special Stakeholders Association meeting this Thursday 📅 to hear how, for the first time, almost all patients with drug-resistant #tuberculosis will be able to be treated with an all-oral, six-month regimen. Register now: https://tballiance.zoom.us/webinar/register/WN_Tms6Sd6VR8yimO0ow4HpDA

Reply on Twitter 1539280251578089477Retweet on Twitter 15392802515780894772Like on Twitter 15392802515780894777Twitter 1539280251578089477
Retweet on TwitterERA4TB Project Retweeted
22 Jun

@amr_d2 representation at the 5th @IMI_ERA4TB consortium meeting. Huge thanks to @SynapseManagers for superb organization of the meeting and to @IMI_ERA4TB memebers for two days of intensive networking.

Reply on Twitter 1539608715686445056Retweet on Twitter 15396087156864450564Like on Twitter 15396087156864450568Twitter 1539608715686445056
Load More...
Acknowledgement:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989.
The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non profit organisation, Bill & Melinda Gates Foundation and University of Dundee.
Contact:
info@era4tb.org
The Project
  • About
  • Objectives
  • Ambitions
  • Structure
Consortium
  • Partners
  • Advisors
News
  • News
  • Newsletter
  • Events
  • Media
Result
  • Publications
  • Deliverables

© 2022 ERA4TB. About IMI - Disclaimer - Cookies Policy - Legal Notice

  • The Project
  • Consortium
  • News
    • Events
    • Press
    • Newsletter
    • Video Library
  • Results
  • TB Facts
  • SharePoint
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookies PolicyACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.